Private Hospitals and Medical Clinics (Amendment) Regulations 2018

Status:

Published in Subsidiary Legislation Supplement
on 28 Feb 2018

No. S 103

Private Hospitals and Medical Clinics Act

(CHAPTER 248)

Private Hospitals and Medical Clinics
(Amendment) Regulations 2018

In exercise of the powers conferred by section 22 of the Private Hospitals and Medical Clinics Act, the Minister for Health makes the following Regulations:

Citation and commencement

1. These Regulations are the Private Hospitals and Medical Clinics (Amendment) Regulations 2018 and come into operation on 28 February 2018.

Amendment of regulation 2

2. Regulation 2(1) of the Private Hospitals and Medical Clinics Regulations (Rg 1) is amended by inserting, immediately after the definition of “registered nurse”, the following definition:

“ “registered pharmacist” means a person registered as a pharmacist under the Pharmacists Registration Act (Cap. 230);”.

New Part IVB

3. The Private Hospitals and Medical Clinics Regulations are amended by inserting, immediately after regulation 56B, the following Part:

“PART IVB

COLLABORATIVE PRESCRIBING SERVICE

Collaborative prescribing service

56C.—(1) Where a private hospital or medical clinic intends to provide a collaborative prescribing service in respect of its patients, the licensee of the private hospital or medical clinic must obtain the prior approval of the Director.

(2) The licensee mentioned in paragraph (1) must make an application to the Director in writing no less than 30 days before the date on which the private hospital or medical clinic intends to commence providing the collaborative prescribing service.

(3) Upon receiving an application under this regulation, the Director may —

(a)	approve the application, subject to such conditions as the Director may think fit to impose; or
(b)	refuse to approve the application.

(4) A licensee which is approved under paragraph (3)(a) must —

(a)

ensure that each collaborative prescribing practitioner —

(i)

has in force a collaborative practice agreement with the following persons before providing a collaborative prescribing service:

(A)	the licensee;
(B)	a medical practitioner who is employed by, or accredited to practise at, the approved institution;

(ii)

provides the collaborative prescribing service only in accordance with the terms of the collaborative practice agreement; and

(iii)

provides the collaborative prescribing service under the supervision of the medical practitioner mentioned in sub‑paragraph (i)(B);

(b)

appoint an employee of the licensee, who satisfies the requirements determined by the Director, to ensure the proper provision of all collaborative prescribing services at the approved institution;

(c)

appoint a credentialing committee for the purposes of —

(i)	approving all collaborative prescribing practitioners who provide a collaborative prescribing service at the approved institution;
(ii)	approving all collaborative practice agreements before they are implemented at the approved institution; and
(iii)	reviewing the provision of collaborative prescribing services by all collaborative prescribing practitioners at the approved institution to ensure compliance with the respective collaborative practice agreements; and

(d)

appoint a service review committee for the purposes of —

(i)	monitoring and reviewing the quality and effectiveness, including conducting audits, of the collaborative prescribing services provided at the approved institution with reference to the standards for the services as determined by the Director;
(ii)	overseeing the implementation of, and compliance with, all collaborative practice agreements at the approved institution;
(iii)	making recommendations to the licensee on the management and resolution of any problems which arise in connection with the collaborative prescribing services provided at the approved institution, and assessing the effectiveness of the recommendations that are implemented by the licensee; and
(iv)	pursuing opportunities for the improvement of the collaborative prescribing services provided at the approved institution.

(5) The Director may require the licensee which is approved under paragraph (3)(a) to furnish any records or information relating to the activities of the committee mentioned in paragraph (4)(c) or (d), as the case may be, as the Director may require.

(6) In this regulation —

“approved institution” means a private hospital or medical clinic whose licensee has been approved by the Director under paragraph (3)(a) to provide a collaborative prescribing service;

“collaborative practice agreement” means a document that sets out the permissible scope of practice of a collaborative prescribing practitioner in an approved institution when providing a collaborative prescribing service, and which includes the following matters:

(a)	the collaborative prescribing service the collaborative prescribing practitioner may provide;
(b)	the conditions under which the collaborative prescribing practitioner may provide the service mentioned in paragraph (a);
(c)	the drug formulary the collaborative prescribing practitioner must adhere to;
(d)	the circumstances under which the collaborative prescribing practitioner is to seek advice from a medical practitioner, or refer a patient to a medical practitioner for clinical management;

“collaborative prescribing practitioner” means a registered nurse or registered pharmacist who is approved by the credentialing committee of an approved institution to provide a collaborative prescribing service.”.

[G.N. Nos. S 223/2003; S 237/2003; S 411/2003; S 308/2008; S 831/2010; S 189/2011; S 450/2013; S 493/2014; S 213/2015; S 450/2015; S 169/2016; S 110/2017; S 430/2017]

Made on 8 February 2018.

CHAN HENG KEE

Permanent Secretary,
Ministry of Health,
Singapore.

[MH 036:014\004-0000; AG/LEGIS/SL/248/2015/1 Vol. 2]

Search within Legislation